Medinol is dedicated to the science of cardiovascular intervention Medinol在支架市场拥有30多年的经验，正在积极改变疾病状态诊断和治疗的模式。 通过设计用于人体多个区域支架的尖端支架，大大减少结构性心脏手术的并发症，并通过植入式微传感器提供对生理指标的实时见解，Medinol展望了未来几年，以创造开创性的医疗设备。 For over 25 years, we have delivered over two million coronary stents to patients worldwide.
Mikaela Testa’s nude ‘revenge selfie’ goes viral | news.com.au
無論是設計用於人體多處進行支架置放的前沿裝置、大幅降低結構性心臟手術的併發症，抑或是藉由植入式感測器提供對於人體生理參數的即時洞察.
'we are pleased to bring technologies to the u.s
That focus both on benefit to patients as well as unique and meaningful advantages to surgeons, allowing for precise stent placement, shorter procedure times and reduced radiation exposure,' said yoram richter, ceo of medinol. 以色列特拉维夫2024年12月26日 /美通社/ -- 全球医疗技术研发领导者Medinol Inc.的全资子公司Microtech宣布，该公司已启动其微型传感器平台的人体临床试验，该试验旨在测量对治疗心故障重要的心房压力。 Medinol’s products constantly stretch the limits of innovation The scientific spirit that led the company to pioneer the revolutionary nir stent in 1996 still drives its multidisciplinary team today.
無論是設計用於人體多處進行支架置放的前沿裝置、大幅降低結構性心臟手術的併發症，抑或是藉由植入式感測器提供對於人體生理參數的即時洞察，Medinol 皆以宏觀視野重新評估現行技術與程序，並以前瞻性的目光擘劃未來，以期開創嶄新裝置，從實質及地域. About medinol founded in 1992, medinol is a privately held company with offices in the u.s And israel, employing over 300 people Extending more than 30 years of experience in the stent market, medinol is aggressively changing paradigms in how disease states are diagnosed and treated.
